Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515992 | 0.83 | HSD11B1 (0.36) | LMNASMN1; SMN2 | |
| SCHEMBL516114 | 0.82 | SRC (0.41) | LMNAHPGDCYP2D6SRCEPHX1 | |
| SCHEMBL9486483 | 0.82 | AKR1C1 (0.43) | CYP2D6SRCNPSR1 | |
| SCHEMBL516116 | 0.81 | PARP1 (0.40) | — | |
| SCHEMBL515733 | 0.78 | GABBR2 (0.41) | LMNACYP2D6EPHX1CYP1A2PKM | |
| SCHEMBL516555 | 0.78 | L3MBTL1 (0.53) | — | |
| SCHEMBL515717 | 0.77 | OPRL1 (0.40) | — | |
| SCHEMBL30632554 | 0.77 | ALDH1A1 (0.40) | LMNAHPGDCYP2D6 | |
| SCHEMBL516571 | 0.77 | ALOX5 (0.42) | ALOX5DPP4 | |
| SCHEMBL516134 | 0.77 | SMN1; SMN2 (0.47) | CYP2D6SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | disclosed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | disclosed |
| EP-2414323-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | Pierre Fabre Médicament (FR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | disclosed |
| WO-2010112597-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | CYP11B2, BCAT1, CYP11B1 | LMNA 2510/4885HPGD 966/4885CYP2D6 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.